Insider Trading
PYXS Stock | USD 1.15 0.05 4.17% |
Slightly above 76 percent of Pyxis Oncology's private investors are selling. The analysis of the overall investor sentiment regarding Pyxis Oncology suggests that a fairly large number of traders are terrified. Pyxis Oncology's investing sentiment can be driven by a variety of factors including economic data, Pyxis Oncology's earnings reports, geopolitical events, and overall market trends.
Pyxis |
Filed transaction by Pyxis Oncology Director . Insider Public Trading
Read at macroaxis.com
Cash Flow Correlation
Pyxis Oncology's cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Pyxis Oncology's relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
Pyxis Oncology Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Pyxis Oncology can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Pyxis Oncology Fundamental Analysis
We analyze Pyxis Oncology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pyxis Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pyxis Oncology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Debt
Total Debt Comparative Analysis
Pyxis Oncology is currently under evaluation in total debt category among its peers. Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Pyxis Oncology Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Pyxis Oncology stock to make a market-neutral strategy. Peer analysis of Pyxis Oncology could also be used in its relative valuation, which is a method of valuing Pyxis Oncology by comparing valuation metrics with similar companies.
Peers
Pyxis Oncology Related Equities
INZY | Inozyme Pharma | 4.12 | ||||
HOOK | Hookipa Pharma | 1.65 | ||||
CRVS | Corvus Pharmaceuticals | 1.39 | ||||
ZURA | Zura Bio | 2.88 | ||||
ELEV | Elevation Oncology | 3.45 | ||||
PDSB | PDS Biotechnology | 3.65 | ||||
TERN | Terns Pharmaceuticals | 5.41 | ||||
MREO | Mereo BioPharma | 5.62 | ||||
ZVSA | ZyVersa Therapeutics | 6.49 | ||||
XFOR | X4 Pharmaceuticals | 13.33 |
Additional Tools for Pyxis Stock Analysis
When running Pyxis Oncology's price analysis, check to measure Pyxis Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pyxis Oncology is operating at the current time. Most of Pyxis Oncology's value examination focuses on studying past and present price action to predict the probability of Pyxis Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pyxis Oncology's price. Additionally, you may evaluate how the addition of Pyxis Oncology to your portfolios can decrease your overall portfolio volatility.